FDG PET in detecting primary and recurrent malignant salivary gland tumors

Clinical Nuclear Medicine

Volumn 32, Issue 4, 2007, Pages 286-291

  Cermik, Tevfik Fikret ^a   Mavi, Ayse ^a   Acikgoz, Gunsel ^a   Houseni, Mohamed ^a   Dadparvar, Simin ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FDG PET; Malignant tumor; Metastasis; Parotid; Recurrence; Salivary gland

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SALIVARY GLAND CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34147187307     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000257336.69537.cb     Document Type: Article

References (25)

1. Laramore GE, Coltrera MD, Hunt KJ. Tumors of salivary glands. In: Rubin P, ed. Clinical Oncology: Multidisciplinary Approach for Physicians and Students. Philadelphia: W.B. Saunders; 2001:451-461.
2. Batsakis JG, Sneige N, el-Naggar AK. Fine-needle aspiration of salivary glands: its utility and tissue effects. Ann Otol Rhinol Laryngol. 1992;101:185-188.
3. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in Oncology. Lancet Oncol. 2001;2:157-164.
4. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32:35-46.
5. Keyes JW Jr, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99-102.
6. Okamura T, Kawabe J, Koyama K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl. 1998;538:209-213.
7. Matsuda M, Sakamoto H, Okamura T, et al. Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland. Acta Otolaryngol Suppl. 1998;538:214-220.
8. Otsuka H, Graham MM, Kogame M, et al. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19:691-694.
9. Mancuso AA. Imaging in patients with head and neck cancer. In: Million RR, Cassisi NJ, eds. Management of Head and Neck Cancer: Multidisciplinary Approach. Philadelphia: Lippincott; 1994:43-59.
10. Vermeersch H, Loose D, Ham H, et al. Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers. Eur J Nucl Med Mol Imaging. 2003;30:1689-1700.
11. Zbaren P, Schar C, Hotz MA, et al. Value of fine-needle aspiration cytology of parotid gland masses. Laryngoscope. 2001;111:1989-1992.
12. Stewart CJ, MacKenzie K, McGarry GW, et al. Fine-needle aspiration cytology of salivary gland: a review of 341 cases. Diagn Cytopathol. 2000;22:139-146.
13. Bartels S, Talbot JM, DiTomasso J, et al. The relative value of fine-needle aspiration and imaging in the preoperative evaluation of parotid masses. Head Neck. 2000;22:781-786.
14. Wong DS, Li GK. The role of fine-needle aspiration cytology in the management of parotid tumors: a critical clinical appraisal. Head Neck. 2000;22:469-473.
15. Touquet R, Mackenzie IJ, Carruth JA. Management of the parotid pleomorphic adenoma, the problem of exposing tumour tissue at operation. The logical pursuit of treatment policies. Br J Oral Maxillofac Surg. 1990;28:404-408.
16. Donovan DT, Conley JJ. Capsular significance in parotid tumor surgery: reality and myths of lateral lobectomy. Laryngoscope. 1984;94:324-329.
17. Myssiorek D, Ruah CB, Hybels RL. Recurrent pleomorphic adenomas of the parotid gland. Head Neck. 1990;12:332-336.
18. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med. 2001;28:816-821.
19. Stokkel MP, ten Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol. 1998;34:466-471.
20. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med. 1995;36:211-216.
21. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med. 1995;36:1747-1757.
22. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med. 2001;28:816-821.
23. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651-658.
24. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-4208.
25. McGuirt WF, Keyes JW Jr, Greven KM, et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope. 1995;105:579-584.